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Abstract
Amyotrophic lateral sclerosis (ALS) is a heterogeneous group of fatal neurodegenerative diseases characterized by a
selective loss of motor neurons in the brain and spinal cord. Creation of transgenic mice expressing mutant Cu/Zn
superoxide dismutase (SOD1), as ALS models, has made an enormous impact on progress of the ALS studies. Recently, it has
been recognized that genetic background and gender affect many physiological and pathological phenotypes. However, no
systematic studies focusing on such effects using ALS models other than SOD1
G93A mice have been conducted. To clarify the
effects of genetic background and gender on gross phenotypes among different ALS models, we here conducted a
comparative analysis of growth curves and lifespans using congenic lines of SOD1
G93A and SOD1
H46R mice on two different
genetic backgrounds; C57BL/6N (B6) and FVB/N (FVB). Copy number of the transgene and their expression between
SOD1
G93A and SOD1
H46R lines were comparable. B6 congenic mutant SOD1 transgenic lines irrespective of their mutation
and gender differences lived longer than corresponding FVB lines. Notably, the G93A mutation caused severer disease
phenotypes than did the H46R mutation, where SOD1
G93A mice, particularly on a FVB background, showed more extensive
body weight loss and earlier death. Gender effect on survival also solely emerged in FVB congenic SOD1
G93A mice.
Conversely, consistent with our previous study using B6 lines, lack of Als2, a murine homolog for the recessive juvenile ALS
causative gene, in FVB congenic SOD1
H46R, but not SOD1
G93A, mice resulted in an earlier death, implying a genetic
background-independent but mutation-dependent phenotypic modification. These results indicate that SOD1
G93A- and
SOD1
H46R-mediated toxicity and their associated pathogenic pathways are not identical. Further, distinctive injurious effects
resulted from different SOD1 mutations, which are associated with genetic background and/or gender, suggests the
presence of several genetic modifiers of disease expression in the mouse genome.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an inexorable neuromus-
cular disorder characterized by progressive loss of motor neurons in
the spinal cord, brainstem and motor cortex [1]. Most ALS patients
become severely paralyzed and die within 3–5 years after diagnosis.
The majority of patients are sporadic (sALS), while 5–10% are
familial cases (fALS), among which approximately 15–20% are
associated with mutations in the gene encoding Cu/Zn superoxide
dismutase (SOD1) [2]. Patients with sALS and mutant SOD1-
linked fALS share many clinical and pathological features [3,4].
Importantly, recent studies have highlighted that not only mutant
SOD1 in fALS but also wild-type SOD1 can be pathogenic in sALS
patients [5,6], illuminating a possible SOD1-dependent pathogenic
mechanism common to sALS and fALS.
To date, more than 160 mutations scattered throughout the
SOD1 protein have been identified in fALS (http://alsod.iop.kcl.
ac.uk/als/). Although mutant SOD1-mediated neuronal toxicity
appears to account for disease expression [7], the exact mechanism
by which mutant SOD1 impairs neuronal function leading to
motor neuron death remains unclear, let alone the clinical
heterogeneity; e.g. age at onset and disease duration, seen within
and/or among SOD1-linked families [3,8,9]. Thus far, it is
generally thought that in addition to the toxic entities associated
with different SOD1 mutations, a complex interplay between other
genetic and environmental factors results in symptomatic variabil-
ity in SOD1-linked fALS.
Genetically engineered mice have played a pivotal role not only
in the molecular pathogenesis but also in the development of
therapeutics for many genetic as well as non-genetic diseases.
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mice expressing a mutant SOD1, has made an enormous impact
on progress of the ALS studies [4,10,11]. More than 10 different
lines of transgenic mouse carrying a different SOD1 mutation, all
of which show a selective degeneration of spinal motor neurons,
have been established [4,11]. Interestingly, the onset and
progression of disease phenotypes appear to vary from line to
line [12,13]. Among these lines, animals carrying a G93A SOD1
mutation (SOD1
G93A) [10] were most widely used and extensively
characterized. Although a copy number of the SOD1
G93A
transgene, and thus expression level of the SOD1
G93A protein, is
a major determinant of disease severity [14], genetic background
and gender may also affect the SOD1
G93A-linked symptoms in mice
[15–17]. It is conceivable that there are some common genetic
modifiers affecting to disease expression in mutant SOD1-
expressing ALS mouse models [15,16]. However, with the use of
only a limited number of lines; i.e. SOD1
G93A, such notions still
remain inconclusive. Further, although it is generally thought that
the different mutant SOD1 proteins are likely to cause motor
neuron disease by a similar mechanism, this idea has also yet to be
fully proven.
Recently, we have generated two congenic mouse lines carrying
either SOD1
G93A or a H46R mutation (SOD1
H46R) on a C57BL/6N
(B6) background [18], and crossed those mice to B6 congenic mice
lacking Als2, a murine homolog for the causative gene for a
number of recessive juvenile motor neuron diseases (MNDs) [19],
generating B6 congenic ALS2-deficient SOD1
G93A and SOD1
H46R
mice [18]. The SOD1
H46R mutation accounts for a mild form of
familial ALS that was originally identified in Japanese kindred
[20,21] and characterized by unusually extended disease duration
after onset [3,21]. Surprisingly, lack of Als2 in B6 congenic
SOD1
H46R, but not SOD1
G93A, mice results in an earlier death [18].
In addition, loss of Gfap, a gene encoding glial fibrillary acidic
protein (GFAP), in B6 congenic SOD1
H46R, but not SOD1
G93A,
mice also accelerates the disease progression [22]. Thus, it is
possible that the SOD1
G93A and SOD1
H46R-mediated pathogenic
mechanisms are not the same. However, at this stage, we could not
formally exclude the possibility that these phenomena are unique
to mice on a B6 background.
In this study, to further clarify the phenotype variability among
different mutant SOD1-expressing ALS mouse models on different
genetic backgrounds, we newly generated congenic lines of
SOD1
G93A and SOD1
H46R mice as well as those lacking Als2 on a
FVB/N (FVB) background, and conducted a comparative analysis
of gross phenotypes in these mutants with different genetic
backgrounds.
Results
Copy numbers of the transgene in SOD1
G93A and
SOD1
H46R transgenic mouse lines with different genetic
backgrounds
In this study, we generated four independent congenic mouse
lines expressing the human mutated SOD1 gene; i.e., C57BL/6N
congenic SOD1
G93A (B6_G93A) and SOD1
H46R (B6_H46R), and
FVB/N congenic SOD1
G93A (FVB_ G93A) and SOD1
H46R (FVB_
H46R). The transgene in each mouse line was transmitted in the
expected Mendelian ratio of an autosomal gene (data not shown).
The previous studies have demonstrated that the estimated copy
numbers of SOD1
G93A and SOD1
H46R in original transgenic lines
are approximately 24 [14] and 20 [23], respectively. Since it has
been shown that a copy number of the mutated SOD1 transgene
affects the disease severity [14], we first analyzed the copy
numbers of the transgene in our mouse lines by quantitative PCR.
The relative number of transgene’s copy was estimated by the
difference in threshold cycle (DCT, delta CT) between the
transgene (SOD1
G93A or SOD1
H46R) and control (mouse Sod1).
There were no significant differences in the DCT values among all
four lines with different transgenes, genetic backgrounds, and/or
genders (Figure 1A and Table 1). These results indicate that each
transgene locus retains comparable number of the mutated SOD1
gene that is stably transmitted in the course of generating our
congenic lines, and that the copy numbers of the transgene
between SOD1
G93A and SOD1
H46R are almost equal.
Figure 1. Copy numbers of the transgene and the levels of its
transcript. (A) Comparison of the difference in threshold cycle (DCT)
between the human SOD1 transgene (SOD1) and a reference mouse
Sod1 gene (Sod1) in SOD1
G93A and SOD1
H46R transgenic mice. There are
no significant differences in the mean values between groups with
different genders (F; female, M; male), genotypes (G93A; SOD1
G93A,
H46R; SOD1
H46R), and genetic backgrounds (B6; C57BL/6, FVB; FVB/N).
(B) Comparison of the DCT between the human SOD1 and the mouse
Actb transcripts in SOD1
G93A and SOD1
H46R transgenic mice. There are no
significant differences in the mean values between groups with
different genders, genotypes, and genetic backgrounds. All values are
mean 6 SD (n=4). Statistical significance is evaluated by ANOVA with
Bonferroni’s post hoc test.
doi:10.1371/journal.pone.0033409.g001
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G93A and
SOD1
H46R transgenic mouse lines with different genetic
backgrounds
To investigate whether the differences in mutations, genetic
backgrounds, and/or genders affect the expression levels of the
mutated SOD1 transcript, we performed a quantitative reverse
transcriptase (qRT)-PCR using total RNA from the spinal cord of
mice at a pre-clinical stage (12 weeks of age). Although the levels of
transcript for SOD1
H46R relative to the b-actin mRNA (Actb)
showed a higher tendency when compared to those for SOD1
G93A,
there were no significant differences in the levels of mutated SOD1
mRNA among different transgenic lines used in this study
(Figure 1B and Table 1). These data indicate that expression
levels of the mutated SOD1 transcripts are affected neither by
difference in mutations, genetic backgrounds, nor genders in mice.
Levels of the mutant SOD1 protein in SOD1
G93A and
SOD1
H46R transgenic mouse lines with different genetic
backgrounds
To examine whether differences in mutations, genetic back-
grounds, and/or genders affect the expression levels of the mutant
SOD1protein,wenextperformed westernblot analysisofthespinal
cord extracts obtained from mice at a pre-clinical stage (12 weeks of
age) using anti-human SOD1 antibody. Although the levels of the
mutant SOD1 proteins slightly varied (Figure 2A and 2B), a
quantitative analysis revealed no statistical differences in the mean
values among all tested mouse lines (Figure 2B and Table 1). Since
the detection efficiency between different SOD1 mutants with
antibody used in this study (polyclonal antibody raised against full-
length SOD1 of human origin) may not necessarily be exactly
equivalent, we could not completely exclude the possibility that
expression levels of SOD1
G93A and SOD1
H46R are different.
Nonetheless, considering comparable levels of both transcripts
(Figure 1B and Table 1), it seems fair to conclude that their protein
levels are also comparable. The results indicate that the expressions
of the mutant SOD1 proteins are not affected by differences in
mutations, genetic backgrounds, and/or genders in mice.
Effects of different mutations on growth curves in SOD1
transgenic mice with different genetic backgrounds
As all four congenic mouse lines generated in this study showed
comparable levels of mutant transgene and protein expressions
(Figure 1, Figure 2, and Table 1), it is assumed that these mutant
SOD1-expressing ALS mouse models could be an appropriate
means to analyze the effects of mutations, genetic backgrounds,
and/or genders on gross phenotypes in vivo. In this study, we first
focused on body weight, as it has been widely accepted that onset
of disease in mutant-SOD1 transgenic ALS mouse models can be
estimated by the reduction of body weight [24,25].
During the experimental periods, both B6 and FVB congenic wild-
type animals showed a constant increase in their body weight,
whereas all the mutant SOD1 mouse lines started losing weight in the
middle (Figure 3A–D). Indeed, both SOD1
G93A and SOD1
H46R mice
with different genetic background exhibited progressive motor
dysfunction and paralysis particularly on the phase of weight
reduction (data not shown). The mean values of body weight for
wild-type animals at each time point were significantly higher than
those for mutant litters, except for those at earlier ages (5–9 weeks) of
male B6_G93A (Figure 3B). The peak mean value of the body weight
in each experimental group ranged from 11 to 18 weeks; 15 week in
female B6_G93A and 15 week in female B6_H46R (Figure 3A), 15
week in male B6_G93A and 18 week in male B6_H46R (Figure 3B),
13 week in female FVB_G93A and 16 week in female FVB_H46R
(Figure 3C), and 11 week in male FVB_G93A and 16 week in male
FVB_H46R (Figure 3D). Notably, SOD1
G93A mice showed more
extensive reduction when compared to SOD1
H46R animals irrespec-
tive of gender and genetic background (Figure 3A–D). Further, both
female and male FVB_G93A exhibited an earlier body weight loss
than FVB_H46R counterparts (Figure 3C and D). These results
support the notion that the H46R mutation in SOD1 results in a
milder disease phenotype than does the G93A mutation in mouse
[18,22] and human [20]. On the other hand, visual inspection of
animal behavior revealed that the onset of disease and the turning
point of the growth curves were closely matched in B6 congenic
mutant SOD1 transgenic mice, as previously reported [24,25].
However, it was obvious that the body weight were persistently
increased at an early phase of disease progression, where animals
clearly showed gait abnormalities, in FVB congenic mutant animals,
particularly in FVB_H46R. Thus, the peak of the growth curve in
mice on a FVB background may not define an earliestsign of disease.
Effects of gender on survival in SOD1
G93A and SOD1
H46R
transgenic mouse lines with different genetic backgrounds
We next focused on lifespan (survival), which is thought to be
one of the most important gross phenotype in ALS mouse models.
Table 1. Summary of the quantitative analysis of the transgenes and their expression.
Strain SOD1mutant Gender n Tg copy number mRNA Protein
(DCt)*a (DCt)*b SOD1/b-actin ratio
B6 G93A F 4 7.5060.80 3.6560.11 1.0460.12
M 4 7.2060.50 3.6460.25 0.9960.29
B6 H46R F 4 7.1060.30 3.6960.08 0.9860.13
M 4 7.2061.10 3.7660.13 1.1560.48
FVB G93A F 4 7.3060.10 3.6960.17 0.9560.30
M 4 7.1060.21 3.6060.20 0.9260.05
FVB H46R F 4 7.4060.34 3.8360.16 1.0960.08
M 4 7.5060.70 3.9660.29 1.0160.24
Values are mean 6 SD.
*aDCt=(Ct for human SOD1)2(Ct for mouse Sod1).
*bDCt=(Ct for human SOD1 mRNA)2(Ct for b-actin mRNA).
doi:10.1371/journal.pone.0033409.t001
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mutations, genetic backgrounds, and/or genders (Table 2),
consistent with previous reports [11,16]. Kaplan-Meier survival
analysis revealed that female FVB_G93A mice lived longer than
male counterpart (Figure 4C). By contrast, no obvious gender
effects on survival in other mouse lines, including B6_G93A
(Figure 4A), B6_H46R (Figure 4B), and FVB_H46R mice
(Figure 4D), were observed. These data suggest that gender
differently affects survival in mice carrying the different SOD1
mutation on a different genetic background.
Effects of genetic background on survival in SOD1
G93A
and SOD1
H46R transgenic mouse lines
We investigated whether genetic background affected on
survival in our congenic mouse lines. Kaplan-Meier survival
analysis revealed that all FVB congenic lines carrying mutant
SOD1 gene irrespective of their mutation and gender differences
showed a significant shorter lifespan when compared to corre-
sponding B6 lines (Figure 5A–D). Namely, compared to the H46R
mutation (Figure 5C and D), devastating effects of the G93A
mutation were more prominent in FVB congenic mice (Figure 5A
and B). These results strongly indicate that difference in genetic
background strongly affects lifespan in mutant SOD1-expressing
ALS mouse models, and suggest that FVB congenic mice are more
susceptible to mutant SOD1-mediated toxic insults than B6 lines.
Effects of different types of the SOD1 mutation on
survival in transgenic mice with different genetic
backgrounds
We next examined whether the different SOD1 mutations
affected survival in mice on the same genetic background and
gender. Kaplan-Meier survival analysis revealed that the G93A
mutation resulted in a shorter lifespan than did the H46R
mutation in both B6 and FVB lines irrespective of gender
(Figure 6A–D). It is noted that such toxic effects of the G93A
mutation were more obvious in mice on a FVB background
(Figure 6C and D). The data suggest that the G93A mutation in
SOD1 causes a severer disease phenotype than does the H46R
mutation, and support the notion that FVB congenic mice are
more susceptible to the SOD1
G93A-mediated toxic insults than B6
lines.
Effect of ALS2 loss on growth curves in FVB congenic
SOD1
G93A and SOD1
H46R transgenic mouse lines
Loss of function mutation in the ALS2 gene accounts for a
number of juvenile recessive forms of ALS/MNDs [19,26,27].
Previously, we demonstrated that genetic ablation of Als2 in
SOD1
H46R, but not SOD1
G93A, mice on a B6 background
aggravated the mutant SOD1-associated disease symptoms and
led to the earlier death [18], suggesting distinctive susceptibilities
to ALS2 loss in different mutant SOD1-expressing ALS mouse
models. In this study, to clarify whether such functional
interactions in vivo between ALS2 and mutant SOD1 depended
on genetic background of mouse lines, we crossed FVB congenic
SOD1
G93A and SOD1
H46R mice to FVB congenic Als2-null mice
[28], generating FVB congenic ALS2-deficient SOD1
G93A (Als2
2/2;
SOD1
G93A) and SOD1
H46R (Als2
2/2;SOD1
H46R) mice (FVB_
G93A_Als22/2 and FVB_H46R_Als22/2), respectively, and
analyzed their body weight and lifespan.
During the experimental periods, the mean values of body
weight for FVB congenic wild-type animals at each time point
were significantly higher than those for all mutant litters
(Figure 7A–D), consistent with the previous findings observed in
B6 congenic lines [18]. There were no significant differences in
body weight between both mutant SOD1 mice and their ALS2-
deficient counterparts (Figure 7A–D), except that male
FVB_H46R_Als22/2 showed a lower value than male
FVB_H46R at 21 weeks of age (Figure 7D). The results suggest
a limited role of ALS2 in growth curve in FVB congenic mutant
SOD1-expressing mice.
Effect of ALS2 loss on survival in FVB congenic SOD1
G93A
and SOD1
H46R transgenic mouse lines
To further investigate the effect of ALS2 loss on survival in FVB
congenic SOD1
G93A and SOD1
H46R transgenic mouse lines, we
analyzed lifespan by Kaplan-Meier analysis. Consistent with the
observation in FVB_G93A and FVB_H46R mice (Figure 4C and
D), there was a small but significant gender difference in
Figure 2. Comparisons of the mutant SOD1 protein levels in
different mutant SOD1 transgenic mouse lines. (A) Representative
data for western blot analysis of the human mutant SOD1 proteins
(hSOD1). The 1% Triton X100-soluble fractions of the spinal cord from
mice at 12 weeks of age with different genders (F; female, M; male),
genotypes (G93A; SOD1
G93A, H46R; SOD1
H46R), and genetic backgrounds
(B6; C57BL/6, FVB; FVB/N) are analyzed. b-actin serves as control. (B)
Quantitative analyses of western blotting for mutant SOD1 in the spinal
cord from 12 week-old mice. Densitometric data for immunoreactive
signals are normalized by the levels of b-actin. There are no significant
differences in the mean values between groups with different genders,
genotypes, and genetic backgrounds. Values are mean 6 SEM (n=4) in
an arbitrary unit. Statistical significance is evaluated by ANOVA with
Bonferroni’s post hoc test.
doi:10.1371/journal.pone.0033409.g002
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ences in FVB_H46R_Als22/2 mice were observed (Figure 8B).
Importantly, as in the case for B6 lines [18], FVB_H46R_Als22/2
mice died earlier than FVB_H46R mice in both gender (Figure 8E
and F), while no differences in lifespan between FVB_
G93A_Als22/2 and FVB_G93A mice were observed (Figure 8C
and D). These results combined with previous findings [18] suggest
a distinctive susceptibility to ALS2 loss in different mutant SOD1-
expressing mice irrespective of their genetic background, and
indicate that the pathogenic pathways associated with ALS2 loss
and SOD1
H46R, but not SOD1
G93A, -mediated neuronal toxicity
might act synergistically in vivo.
Discussion
In the present study, we generated four congenic ALS mouse
model lines; SOD1
G93A and SOD1
H46R mice on two different
genetic backgrounds; B6 and FVB, and showed that the expression
levels of the mutant SOD1 proteins among these different lines
were comparable. This allows us to conduct a comparative
analysis of growth curve and survival using these mice,
demonstrating some concrete evidence indicating that two
different SOD1 mutations exerts a distinct harmful effect on gross
phenotypes in mice.
Multiple epidemiological surveys have indicated that gender
affects the incidence, age at onset, and disease duration in sALS
patients [29,30]. However, the male-to-female ratio in the SOD1-
linked fALS patients is 1:1 [3], rather suggesting the absence of
gender effects in human ALS patients with the SOD1 mutations.
Nonetheless, it has been reported that female mice lived longer
than male in several different congenic SOD1
G93A lines on a SJL/J
(SJL), C3H/HeJ (C3H), BALB/cByJ (BALB), and FVB back-
grounds, while neither B6 nor DBA/2J (DBA) congenic mice
showed any gender effects on lifespan [15,16]. Consistently, we
here showed that female FVB, but not B6, congenic SOD1
G93A
mice lived longer than corresponding male counterpart, confirm-
Figure 3. Growth curves for two different mutant SOD1 transgenic mouse lines with different genetic backgrounds. (A) Growth curves
for C57BL/6 (B6) congenic female mice [wild-type (B6_WT F; open triangle, n=9–10), SOD1
G93A (B6_G93A F; closed circle, n=7–22), SOD1
H46R
(B6_H46R F; open square, n=8–30)]. (B) Growth curves for B6 congenic male mice [wild-type (B6_WT M; open triangle, n=15–17), SOD1
G93A
(B6_G93A M; closed circle, n=6–16), SOD1
H46R (B6_H46R M; open square, n=24–46)]. (C) Growth curves for FVB/N (FVB) congenic female mice [wild-
type (FVB_WT F; open triangle, n=9–16), SOD1
G93A (FVB_G93A F; closed circle, n=9–27), SOD1
H46R (FVB_H46R F; open square, n=14–20)]. (D) Growth
curves for FVB congenic male mice [wild-type (FVB_WT M; open triangle, n=15–19), SOD1
G93A (FVB_G93A M; closed circle, n=6–17), SOD1
H46R
(FVB_H46R M; open square, n=23–28)]. (A–D) Data are omitted from analysis when the numbers of live animals of the particular genotype at a
particular age are ,6. Values are mean 6 SD. Statistical significances are evaluated by ANOVA with Bonferroni’s post hoc test. In either gender or
genetic background, degrees of body weight loss associated with disease progression in SOD1
G93A mice are greater than those in SOD1
H46R mice
(*p,0.05, **p,0.01, ***p,0.001, ****p,0.0001). The values either for SOD1
G93A or SOD1
H46R mice, except for male B6 SOD1
G93A mice earlier than 9
weeks of ages, are all significantly lower than those for age-matched WT animals (levels of significance are not shown).
doi:10.1371/journal.pone.0033409.g003
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dependent gender-specific harmful effect in mice. Interestingly,
unlike SOD1
G93A mice, both B6 and FVB congenic mice
expressing SOD1
H46R showed no observable gender effect on
survival. Together, not only genetic background but also
difference in the SOD1 mutations may affect the gender-associated
phenotypic modification, at least, in mice.
In addition to gender effects as above, it is widely appreciated
that genetic background affects many phenotypes including
lifespan in mutant SOD1-expressing ALS mouse models
[15,16,31,32]. Likewise, Als2-null mice, another type of ALS/
MND model, on a FVB but not B6 background shows shorter
lifespan than do wild-type litters [28]. Consistently, we here
revealed that both FVB congenic SOD1
G93A and SOD1
H46R lines
exhibited a significant shorter lifespan when compared to B6
counterparts. It is noted that the mutant SOD1-mediating
devastating effects on life span appear more prominent in
SOD1
G93A than SOD1
H46R mice, particularly those on a FVB
background. FVB mice are known to be more vulnerable to
glutamate receptor-mediated excitotoxic cell death [33,34], as well
as to mitochondrial toxin-mediated metabolic cell death [35],
when compared to B6 mice. These findings suggest that FVB
congenic mice may have certain properties involving in the
preferential vulnerability to cellular-toxicities including mutant
SOD1-mediated insults. Conversely, it is equally likely that B6
mouse carries the gene conferring the resistance to these insults.
One of the important findings obtained from this study was that
the different SOD1 mutations showed distinct adverse effects on
gross phenotypes in ALS/MND mouse models. Comparative
analysis of growth curves and lifespans revealed that the G93A
mutation in SOD1 caused a severer disease phenotype than did the
H46R mutation, where SOD1
G93A mice showed more extensive
body weight loss and earlier death. These trends were more
striking in FVB congenic mice. Remarkably, lack of Als2, a murine
homolog for the recessive juvenile ALS causative gene [19], in
FVB congenic SOD1
H46R, but not SOD1
G93A, mice resulted in an
earlier death. We have previously demonstrated similar results
using B6 congenic Als2-deficient SOD1
H46R but not SOD1
G93A mice
[18], indicating a genetic background-independent but mutation-
dependent phenotypic modification. Although the possibility that
phenotypic variances observed are due to locus-specific effects of
each transgene and/or adjacent genes in a particular genomic
region should not be excluded, these findings lend credence to the
notion that SOD1
G93A- and SOD1
H46R-mediated toxicity and
their associated pathogenic pathways are not identical. Recent
findings that loss of Gfap, a gene encoding glial fibrillary acidic
protein (GFAP), in B6 congenic SOD1
H46R, but not SOD1
G93A,
mice slightly accelerates the disease progression [22], also support
this idea.
Provided that the SOD1
G93A and SOD1
H46R mutants exert the
distinctive harmful effects on symptoms associated with ALS/
MNDs, how does different mutation in the same gene result in the
distinctive phenotypic modification? It has been reported that
although age at onset among families carrying different SOD1
mutations with high penetrance is less variable with the mean
value ranging from 45 to 50 years [3], the mean disease duration
after onset varies depending on mutation type, with a range of 0.9
to 18.7 years among SOD1-linked families [3]. Indeed, the disease
durations after onset in patients with the G93A and H46R
mutations are considerably different (G93A vs H46R; 2.261.5 vs
17.0611.0 years) [3,21]. It is noted that our congenic ALS mouse
models partly recapitulate such differences. Currently, although
exact molecular basis for the mutation-dependent effect remains
unclear, it is appreciated that the SOD1-mediated dismutase
enzymatic activity is not a major determinant for the phenotypic
modification, since there is no correlation between disease
severities and the SOD1 dismutase activities [36,37]. Rather, the
differences in the propensity for the aggregate formation among
the different mutant SOD1 proteins might be related [7,38]. In
cultured cells, SOD1
H46R mutant forms fewer insoluble aggregates
and inclusions when compared with SOD1
G93A [38]. Further,
unlike in SOD1
G93A mice [39], no obvious SOD1-positive
inclusions are detected in the spinal cord of SOD1
H46R mice
[18]. These results indicate that SOD1
H46R is less prone to form
aggregates than SOD1
G93A. Additionally, large vacuolar structures
originated from distended mitochondria are evident in SOD1
G93A
[12], while such pathological features are barely observed in
SOD1
H46R mice. Instead, a widespread axonal pathology and
degeneration considerably precede motor neuron loss in the spinal
cord of SOD1
H46R mice [18,23]. Thus, it is conceivable that
molecular basis for the pathogenesis in each mutant SOD1-
expressing mouse model may not be the same.
It is generally thought that symptomatic heterogeneity observed
in patients with ALS/MNDs may reflect varied etiology and/or
results from a complex interplay between other genetic and
environmental factors [8,9,40]. Some epidemiological studies
suggest that traumatic injury and exercise are risk factors for the
development of ALS [41,42], but these results were not widely
confirmed [43]. Animal studies using a SOD1
G93A ALS model have
demonstrated that extensive endurance exercise hastens a decrease
in motor performance and death following onset of disease in male
mice [44], while moderate exercise seems to be beneficial [45].
Further, it has recently been shown that environmental enrich-
ment significantly improves motor performance in SOD1
G93A mice
in a gender-specific manner [46]. However, it is still unclear as to
whether and how such environmental factors affect disease
symptoms. Future studies using different congenic ALS mouse
models are warranted to clarify not only genetic but also such
environmental factors associated with ALS/MNDs.
Preclinical animal studies are prerequisite for the development
of therapeutic agents for the treatment of ALS/MNDs. Thus far, a
large number of successful therapeutic interventions in preclinical
animal studies have failed to translate into human applications
Table 2. Lifespan of the mutant SOD1 transgenic mouse lines
used in this study.
Strain Genotype Gender n Lifespan (Survival)
(days)*
B6 SOD1
G93A F 19 159.868.2
M 15 158.668.7
B6 SOD1
H46R F 31 163.4613.9
M 63 166.6610.6
FVB SOD1
G93A F 20 135.8610.7
M 17 125.969.0
FVB SOD1
H46R F 20 156.163.3
M 27 152.967.3
FVB SOD1
G93A;Als2
2/2 F 13 133.269.9
M 8 126.467.3
FVB SOD1
H46R;Als2
2/2 F 12 147.864.9
M 10 142.5612.3
*Values are mean 6 SD.
doi:10.1371/journal.pone.0033409.t002
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for preclinical animal studies for ALS/MNDs has recently been
proposed [47], in which in addition to the minimum experimental
requirementsforany proofofconceptorpreclinicalstudy,theuse of
not only SOD1
G93A model but also other potential ALS models such
as transgenic mice expressing either mutant dynactin, TAR DNA-
binding protein (TDP43), or fused in sarcoma (FUS) mutants are
recommended. However, the trend is still largely biased toward the
use of single mutant SOD1 ALS mouse model; i.e., SOD1
G93A [47].
We here propose that mice expressing SOD1 mutants other than
SOD1
G93A should also be included within this list. It seems logical
that convincing evidences could be obtained by replicated
demonstrations of efficacy and effectiveness of interventions with
different ALS models in preclinical animal studies.
In conclusion, the findings presented in this study strongly
support the notion that the different mutant SOD1 proteins cause
motor neuron dysfunction and death by a similar but not identical
mechanism, suggesting the presence of different genetic modifiers
of disease expression, which are associated with a combination
with particular SOD1 mutation, genetic background, and/or
gender. Thus, congenic ALS mouse models with different SOD1
mutations generated in this study should provide a useful means
not only for the identification of modifier genes as well as
environmental factors associated with ALS/MNDs, but also for
preclinical animal studies in ALS/MNDs.
Materials and Methods
Ethics statement
All animal experimental procedures were carried out in accord
with the Fundamental Guidelines for Proper Conduct of Animal
Experiment and Related Activities in Academic Research
Institutions under the jurisdiction of the Ministry of Education,
Culture, Sports, Science and Technology, Japan, and reviewed
and approved by The Institutional Animal Care and Use
Committee at Tokai University.
Figure 4. Effect of gender on survival in different mutant SOD1 transgenic mouse lines. (A) Survival curves for C57BL/6 (B6) congenic
SOD1
G93A transgenic mice (B6_G93A) [female (F); closed circle: n=19, male (M); open square: n=15]. (B) Survival curves for B6 congenic SOD1
H46R
transgenic mice (B6_H46R) (F; closed circle: n=31, M; open square: n=63). (C) Survival curves for FVB/N (FVB) congenic SOD1
G93A transgenic mice
(FVB_G93A) (F; closed circle: n=20, M; open square: n=17). (D) Survival curves for FVB congenic SOD1
H46R transgenic mice (FVB_H46R) (F; closed
circle: n=20, M; open square: n=27). Kaplan-Meier analysis with Log-rank (Mantel-Cox) test reveals a significant gender difference in FVB_G93A
(p=0.003), but not in B6_G93A (p=0.7344), B6_H46R (p=0.3723), and FVB_H46R (p=0.4439).
doi:10.1371/journal.pone.0033409.g004
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We generated C57BL/6N (B6) congenic SOD1
H46R mice by
crossing original SOD1
H46R-tg males (C57BL/66DBA/2) [23] to
B6 females for more than 16 generations (.N16). Then, B6
congenic SOD1
H46R-tg males were backcrossed to FVB/NJcl (FVB)
females for more than 10 generations (.N10), generating FVB
congenicSOD1
H46Rlines.CongenicSOD1
G93Amice ontwodifferent
genetic backgrounds were also generated by crossing B6SJL-
TgN(SOD1-G93A)1Gurmales (C57BL/6J6SJL) [10]derived from
Jackson Laboratories to either B6 or FVB females for more than 10
generations (.N10). In addition, we newly generated two FVB
congenic lines of double mutants; Als2
2/2;SOD1
H46R and Als2
2/2;
SOD1
G93A. FVB congenic lines of Als2
+/2 mice generated by
crossing F2 Als2
+/2 mice (129P26B6) [48] to FVB mice for more
than 10 generations (.N10) [28] were utilized to produce FVB
congenic Als2
+/2;SOD1
H46R and Als2
+/2;SOD1
G93A mice. We
crossed FVB congenic SOD1
H46R or SOD1
G93A males to FVB
congenic Als2
+/2 female mice, generating mice with nine different
genotypes; Als2
+/+ (wild-type), Als2
+/2, Als2
2/2, Als2
+/+;SOD1
H46R,
Als2
+/2;SOD1
H46R, Als2
2/2;SOD1
H46R, Als2
+/+;SOD1
G93A, Als2
+/2;
SOD1
G93A,a n dAls2
2/2;SOD1
G93A, by crossing male Als2
+/2;
SOD1
H46R or Als2
+/2;SOD1
G93A to female Als2
+/2 mice. Among
these animals, wild-type, Als2
+/+;SOD1
H46R, Als2
2/2;SOD1
H46R,
Als2
+/+;SOD1
G93A, and Als2
2/2;SOD1
G93A mice were used in this
study. Mice were genotyped by PCR using genomic DNA from tail
tissues as described [18,48]. Mice were housed at 22–23uC with a
12 hr light/dark cycle. Food and water were fed ad libitum. Body
weight of each animal was weekly monitored. Their lifespan
(endpoint) was determined by the observation that mice were
unable to move by themselves.
Analysis of the copy number of the SOD1 transgene
The copy numbers of the human SOD1 transgene in the mouse
genome was estimated using real time quantitative PCR by
Figure 5. Effect of genetic background on survival in different mutant SOD1 transgenic mouse lines. (A) Survival curves for C57BL/6 (B6)
congenic SOD1
G93A transgenic female mice (B6_G93A F) (closed circle: n=19) and FVB/N (FVB) congenic SOD1
G93A transgenic female mice (FVB_G93A
F) (open square: n=20). (B) Survival curves for B6 congenic SOD1
G93A transgenic male mice (B6_G93A M) (closed circle: n=15) and FVB congenic
SOD1
G93A transgenic male mice (FVB_G93A M) (open square: n=17). (C) Survival curves for B6 congenic SOD1
H46R transgenic female mice (B6_H46R F)
(closed circle: n=31) and FVB congenic SOD1
H46R transgenic female mice (FVB_H46R F) (open square: n=20). (D) Survival curves for B6 congenic
SOD1
H46R transgenic male mice (B6_H46R M) (closed circle: n=63) and FVB congenic SOD1
H46R transgenic male mice (FVB_H46R M) (open square:
n=27). Kaplan-Meier analysis with Log-rank (Mantel-Cox) test identifies significant differences in survival for mutant SOD1 transgenic lines between
B6 and FVB backgrounds (p,0.0001).
doi:10.1371/journal.pone.0033409.g005
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human SOD1 transgene and a reference mouse gene (Sod1).
Primers used in this study were as follows: human SOD1; forward
(F): 59-TGCCAGCAGAGTACACAAG-39, reverse (R): 59-AT-
CAAAGCCCAGTTTTGTGG-39, mouse Sod1;F :5 9-GAT-
TGGGTTTGACCCATTTG-39,R :5 9-GCTCAACAATGCAG-
CAAGTC-39. The real time PCR was performed in a 20 ml
reaction mixture containing genomic DNA (10 ng), primers mix
(final primer concentration of 500 nM each), and SYBR Green
PCR Master Mix (QuantiFast SYBR Green PCR Kit; Qiagen) in
a MicroAmp 96 well plate (Applied Biosystems) using 7500 Fast
Real-Time PCR System (Applied Biosystems). The thermal
conditions were the initial denaturation at 95uC for 5 min
followed by 40 cycles of 95uC for 10 sec and 60uC for 30 sec.
Preparation protein and total RNA samples
Spinal cord tissues were weighed and homogenized in 2 weight-
volume (mg/ml) of phosphate buffer saline (PBS). A fraction (25 ml)
of the homogenates was subjected to RNA extraction, and the
remaining of them was used for protein extraction as described
[22]. In brief, total RNA was extracted from tissue homogenates
using Sepazole RNA I super G (Nacalai Tesque), and purified by
SV Total RNA Isolation System (Promega) according to the
manufacturer’s instructions. Protein samples were obtained from
the remaining tissue homogenates by lysing with buffer A [25 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 1% (w/v) Triton X-100 (TX),
Complete Protease Inhibitor Cocktail (Roche)], followed by
centrifugation at 23,0006g for 20 min at 4uC. The resultant
supernatant was collected as a TX-soluble protein fraction. Protein
concentration of each fraction was determined by the Micro BCA
or Pierce 660 nm Protein Assay system (Thermo Scientific).
Quantitative reverse transcriptase-PCR
The quantitative reverse transcriptase (qRT)-PCR was per-
formed on a 0.5 ng of total RNA using QuantiFast SYBR Green
RT-PCR (Qiagen) with specific primers (0.6 mM each) as follows;
human SOD1;F :5 9-AGGGCATCATCAATTTCGAG-39,R :5 9-
ACATTGCCCAAGTCTCCAAC-39, mouse Actb (b-actin); F: 59-
Figure 6. Effect of different types of the SOD1 mutation on survival. (A) Survival curves for C57BL/6 (B6) congenic SOD1
G93A transgenic
female mice (B6_G93A F) (closed circle: n=19) and B6 congenic SOD1
H46R transgenic female mice (B6_H46R F) (open square: n=31). (B) Survival
curves for B6 congenic SOD1
G93A transgenic male mice (B6_G93A M) (closed circle: n=15) and B6 congenic SOD1
H46R transgenic male mice (B6_H46R
M) (open square: n=63). (C) Survival curves for FVB/N (FVB) congenic SOD1
G93A transgenic female mice (FVB_G93A F) (closed circle: n=20) and FVB
congenic SOD1
H46R transgenic female mice (FVB_H46R F) (open square: n=20). (D) Survival curves for FVB congenic SOD1
G93A transgenic male mice
(FVB_G93A M) (closed circle: n=17) and FVB congenic SOD1
H46R transgenic male mice (FVB_H46R M) (open square: n=27). Kaplan-Meier analysis with
Log-rank (Mantel-Cox) test identifies significant differences in survival between B6_G93A F and B6_H46R F (p=0.0210), B6_G93A M and B6_H46R M
(p=0.0004), FVB_G93A F and FVB_H46R F (p,0.0001), and FVB_G93A M and FVB_H46R M (p,0.0001).
doi:10.1371/journal.pone.0033409.g006
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GTGGTGAAG-39. The thermal cycling conditions consisted of a
30 min of reverse transcription step at 50uC, 10 min of initial
denaturation at 95uC, followed by 40 cycles of amplification steps
of 95uC for 15 sec and 60uC for 30 sec. The levels of the SOD1
transcripts were analyzed by determining the difference in DCT
between the human SOD1 and the mouse Actb transcripts in each
sample.
Antibodies and western blot analysis
Primary antibodies used for western blot analysis included
rabbit polyclonal anti-SOD1 (1:50,000, Santa Cruz, FL-154) and
anti-b-actin (1:1000, Sigma, A-5060) antibodies. Secondary
antibody was horseradish peroxidase (HRP)-conjugated donkey
anti-rabbit IgG (1:5000, Amersham Bioscience). Equal amount of
proteins (1–2 mg) were electrophoretically separated by a SDS-
polyacrylamide gel (SuperSep Ace, 5–20% WAKO) and trans-
ferred onto a polyvinylidine difluride membrane (Bio-Rad). The
membranes were blocked with Blocking One (Nacalai Tesque) for
2 hr at room temperature, and incubated with the appropriate
primary antibody in TBST [20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 0.1% (w/v) Tween 20] containing 5% Blocking One
(Nacalai Tesque). After washing with TBST, membranes were
incubated with HRP-conjugated secondary antibody at room
temperature for 2 hr, followed by a repeated wash with TBST.
Signals were visualized by Immobilon Western (Millipore) and X-
ray film (Amersham Bioscience), and were quantified by analyzing
the digitally captured images using CS Analyzer ver3 (ATTO).
Figure 7. Growth curves for ALS2 deficient SOD1 transgenic mice on a FVB background. (A) Growth curves for FVB/N (FVB) congenic
female mice [wild-type (FVB_WT F; open triangle, n=9–16), SOD1
G93A (FVB_G93A F; closed circle, n=9–27), SOD1
G93A;Als2
2/2 (FVB_G93A_Als22/2 F;
open square, n=5–20)]. (B) Growth curves for FVB congenic male mice [wild-type (FVB_WT M; open triangle, n=15–19), SOD1
G93A (FVB_G93A M;
closed circle, n=6–17), SOD1
G93A;Als2
2/2 (FVB_G93A_Als22/2 M; open square, n=4–10)]. (C) Growth curves for FVB congenic female mice [wild-type
(FVB_WT F; open triangle, n=9–16), SOD1
H46R (FVB_H46R F; closed circle, n=14–20), SOD1
H46R;Als2
2/2 (FVB_H46R_Als22/2 F; open square, n=8–
15)]. (D) Growth curves for FVB congenic male mice [wild-type (FVB_WT M; open triangle, n=15–19), SOD1
H46R (FVB_H46R M; closed circle, n=19–28),
SOD1
H46R;Als2
2/2 (FVB_H46R_Als22/2 M; open square, n=4–10)]. (A–D) Data are omitted from analysis when the numbers of live animals of the
particular genotype at a particular age are ,4. Values are mean 6 SD. Statistical significances are evaluated by ANOVA with Bonferroni’s post hoc test.
Degree of body weight loss associated with disease progression in male FVB SOD1
H46R mice is greater than that in male FVB SOD1
H46R;Als2
2/2
SOD1
H46R mice (***p,0.001). The values for all mutant SOD1 transgenic mice with or without ALS2 are significantly lower than those for age-matched
WT animals (levels of significance are not shown).
doi:10.1371/journal.pone.0033409.g007
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Statistical analyses were conducted using PRISM5 (GraphPad).
Statistical significance was evaluated by ANOVA followed by
appropriate post hoc tests for multiple comparisons between groups.
Survival data were compared using Kaplan-Meier survival analysis
with Log-rank (Mantel-Cox) test. A p-value,0.05 was considered
as reaching statistical significance.
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